DIALUNOX supports US diagnostics company QUIDEL in fighting against the COVID crisis providing the suitable instrument platform for molecular analysis of SARS-CoV-2 infections.
On Dec 23rd, Quidel Corporation announced FDA emergency use authorization of its SARS-CoV-2 assay running on the Solana platform, manufactured by DIALUNOX GmbH. The Solana SARS-CoV-2 Assay is an isothermal Reverse Transcriptase – Helicase-Dependent Amplification (RT-HDA) assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal (NP) and nasal (NS) swab specimens from individuals suspected of COVID-19 by their healthcare provider.
The availability of this test on the Solana platform will allow users to get results of up to 11 patient samples in less than 30 minutes. This will be a tremendous step forward in ramping up patient screening in decentralized settings with limited space available. Solana system has a small footprint of only 23 x 20 cm (9 x 8 in).
DIALUNOX GmbH has already provided more than 2000 Solana units to its partner Quidel, ramping up the capacity to fulfill the increased demand.
The Solana product fits perfectly our purpose statement which is to enable faster and better decisions where it’s needed most.
The US healthcare system will now have an additional powerful tool available together with the SARS-CoV-2 Assay on Solana platform which will allow to narrow down the pandemic and locate new hotspots at a much earlier stage.
